In Western countries, there has been a resurgence of syphilis since 2000 \[[@CIT0001]\], with a peak prevalence in men who have sex with men (MSM) living with HIV \[[@CIT0002], [@CIT0003]\]. HIV infection has been associated with lower rates of serologically defined treatment responses, compared with the rates that have been observed in the general population \[[@CIT0004], [@CIT0005]\], although conflicting results on this topic have been reported \[[@CIT0006], [@CIT0007]\].

A few studies \[[@CIT0004]\] have investigated for predictors of treatment response of syphilis in people living with HIV (PLWH), showing controversial results \[[@CIT0004]\].

Different guidelines \[[@CIT0012], [@CIT0013]\] have recommended the same treatment regimens for PLWH and the general population, regardless of the stage of syphilis; however, concerns regarding the treatment of syphilis in PLWH remain. A high proportion of clinicians who care for patients with HIV continue to use 3 doses of benzathine penicillin G (BPG) to treat early syphilis \[[@CIT0009], [@CIT0014]\] because of possible concerns regarding the lower efficacy of the recommended 1-dose BPG regimen. Additionally, limited data \[[@CIT0015], [@CIT0016]\] are available on the efficacy of the alternative regimen, doxycycline, especially for the treatment of late latent syphilis.

Therefore, the aims of this study were to evaluate the response rate of treatment of syphilis in a large cohort of PLWH and to identify treatment response predictors (including different treatment regimens) in early and late stages of syphilis.

METHODS {#s1}
=======

This retrospective, longitudinal study was approved by the Ethics Committee of the San Raffaele Scientific Institute (approval No. 34--2017) and evaluated data from the HIV Clinic of San Luigi Center, San Raffaele Hospital, in Milan, Italy.

In the present study, we included PLWH who were diagnosed with and treated for syphilis between January 2004 and June 2016 (freezing date). A nontreponemal test (rapid plasma reagin \[RPR\], RPR Plus, Diesse Srl, Monteriggioni (SI), Italy) and a treponemal test (*Treponema pallidum* hemagglutination assay \[TPHA\], Mycrosyph TPHA, Axis Shield, Dundee, Scotland) were used for the diagnosis of syphilis.

The detection of positive titers in patients without a history of previously treated syphilis and with previous negative RPR and TPHA titers indicated a patient's first diagnosis of syphilis. Among patients with documented previous treatment(s), a seroconversion of the RPR titer (if previously negative) or a ≥4-fold increase in RPR titer was considered a new episode of syphilis (re-infection).

The syphilis stages were classified as early (primary, secondary, and early latent) or late (tertiary and late latent) according to the clinical examination, patient's history, and timing of infections. Primary syphilis was diagnosed in the presence of RPR and TPHA titers that were compatible with a syphilis episode, and the concomitant presence of a single or multiple genital, perineal, perianal, or rectal (if an anoscopy/rectoscopy was performed) ulcers. A case of secondary syphilis was diagnosed in the presence of treponemal and nontreponemal titers that were suggestive of a syphilis episode and a concomitant maculopapular skin rash and/or mucous patches/condylomata lata and/or constitutional symptoms (fever, diffuse lymphadenopathy, malaise). Patients with positive RPR and TPHA titers and cardiovascular involvement or gummas were diagnosed with tertiary syphilis.

Asymptomatic subjects with RPR and TPHA titers suggestive of a syphilis episode were diagnosed with early latent syphilis if a previous syphilis serology was available, was not compatible with an active infection, and was performed no later than 1 year before the current syphilis episode. Otherwise, asymptomatic patients were diagnosed with late latent syphilis.

All syphilis diagnoses that were without a documented history of treatment or an available serologic follow-up or neurosyphilis cases (because of the different treatments and diagnostic approaches) were excluded from the analysis. Serological treatment response was defined as a ≥4-fold decline---2 dilutions (eg, from 1:64 to 1:16)---in RPR titers or a reversion to nonreactive (if RPR ≤ 1:4 at diagnosis) 12 months after treatment for early syphilis or 24 months after treatment for late syphilis in the absence of documented re-infection \[[@CIT0012]\].

Serofast status \[[@CIT0011]\] was diagnosed in subjects who experienced a single episode of syphilis during the study period and who were successfully treated but did not revert their RPR titers to nonreactive by the end of the study.

Data Analysis {#s2}
-------------

Results were described as median (interquartile range \[IQR\]) or frequency (%). Continuous and categorical variables were compared with the nonparametric Kruskal-Wallis test, Mann-Whitney rank-sum test, and the chi-square or Fisher exact test.

The Cochran-Mantel-Haenszel test was applied to assess linear trend over time of BPG use.

Different definitions of the study follow-up period were used in relation to the considered outcome. With regards to the estimate of the incidence rates of syphilis, the study follow-up accrued from the date of the first visit to the last available visit, or the freezing date minus the days that were required to treat syphilis (ie, total follow-up time minus time to treat syphilis).

With regards to the estimate of the incidence rates of treatment response, the follow-up time was accrued from the date of syphilis diagnosis to (1) the date of treatment response or (2) in case of a lack of response to treatment, 12 or 24 months from diagnosis of early and late syphilis episodes, respectively. To evaluate for serofast status, the time of follow-up was accrued from the date of syphilis diagnosis to the date of sero-reversion, or the date of the last available visit.

The crude incidence rates of syphilis (95% confidence intervals \[CIs\]) were expressed per 1000 person-years of follow-up (PYFU) and calculated as the total number of episodes divided by the cumulative study follow-up at risk for syphilis, contributed by all subjects. The crude incidence rates of treatment response (95% CIs) were expressed per 1000 person-months of follow-up (PMFU) and calculated as the total number of episodes of treatment response divided by cumulative follow-up at risk contributed by all subjects.

Incidence rates were estimated and compared by use of Poisson regression models. The Andersen-Gill extension of the Cox regression model for recurrent events was used to model treatment success on the individual level with a robust (sandwich) variance estimator to account for the matched nature of the sample \[[@CIT0017]\]. The adjusted hazard ratios (HRs) of serofast response and the corresponding 95% CIs were reported.

Further multivariate Cox proportional hazard models were calculated to identify factors that were associated with a serofast response in the overall sample and in the early syphilis subgroup. The factors that were associated with serofast response among subjects with late syphilis were not calculated because of the low sample size (9 serofast responses among 58 patients with late syphilis). All these models included the same covariates that were used in the models on treatment response.

All of the statistical tests were two-sided at the 5% level and were performed using SAS software (release 9.4; SAS Institute).

RESULTS {#s3}
=======

During 44 543 PYFU, 863 episodes of syphilis were recorded in 584 subjects, for an overall incidence rate of 19.4 (18.1--20.7)/1000 PYFU, with a higher incidence of syphilis observed in more recent years (before 2010: 12.9 \[11.5--14.4\]/1000 PYFU; 2010--2012: 24.6 \[21.8--27.4\]/1000 PYFU; after 2012: 27.0 \[23.9--30.1\]/1000 PYFU; *P* \< .0001).

Thirty-four diagnoses in 20 subjects were excluded because of the lack of RPR titers obtained after treatment or the absence of a documented treatment after diagnosis, or if there was a diagnosis of neurosyphilis.

Thus, data were analyzed from 564 subjects for a total of 829 diagnoses of syphilis with assessable serological responses. In these subjects, the median number of concomitant RPR and TPHA titer determinations per year was 2.8 (2.3--3.5).

After syphilis treatment, the first RPR determination was performed 3.9 (2.7--5.4) months after therapy.

Among the 829 episodes, 686 (83%) were diagnosed as early syphilis, 97 (14%) were primary syphilis, 239 (35%) were secondary syphilis, and 350 (51%) were early latent syphilis. Among the 143 late syphilis, 136 (95%) cases of late latent and 7 (5%) cases of tertiary syphilis were observed. Characteristics of syphilis episodes according to disease stage are reported in [Table 1](#T1){ref-type="table"}, whereas [Figure 1](#F1){ref-type="fig"} shows the calendar-year distribution of syphilis diagnoses, according to syphilis type.

###### 

Characteristics of the 829 Syphilis Episodes (Early and Late) With an Assessable Treatment Response Observed During the Study Period (January 1, 2004--June 30, 2016) and Included in the Analysis; HIV Clinic of San Luigi Center, San Raffaele Hospital, Milan, Italy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                    Early Syphilis                                                Late Syphilis                                 All Syphilis\   Overall^a^\   Early vs Late\
                                                                                                                                                 (n=829)         *P*-value     *P*-value
  ---------------------------------- ---------------- -------------- -------------- -------------- --------------- -------------- -------------- --------------- ------------- ----------------
  First infection                    30 (31%)         88 (37%)       75 (21%)       193 (28%)      1 (14%)         43 (32%)       44 (31%)       237 (29%)       0.001^d^      0.542^d^

  RPR titer at diagnosis                                                                                                                                                       

  ≤1:32                              67 (69%)         100 (42%)      239 (68%)      406 (59%)      2 (29%)         99 (73%)       101 (71%)      507 (61%)       \<.0001^d^    0.011^d^

  TPHA titer at diagnosis                                                                                                                                                      

  \>1:5120                           70 (72%)         194 (81%)      259 (74%)      523 (76%)      7 (100%)        92 (68%)       99 (69%)       622 (75%)       0.020^d^      0.089^d^

  Treatment regimens                                                                                                                                                           

  One-dose BPG                       25 (26%)         48 (20%)       102 (29%)      175 (26%)      0               0              0              175 (21%)       \<.0001^d^    \<.0001^d^

  Three-dose BPG                     54 (56%)         165 (69%)      216 (62%)      435 (63%)      7 (100%)        119 (87%)      126 (88%)      561 (68%)                     

  Doxycycline                        12 (12%)         18 (8%)        25 (7%)        55 (8%)        0               17 (13%)       17 (12%)       72 (9%)                       

  Other                              6 (6%)           8 (3%)         7 (2%)         21 (3%)        0               0              0              21 (3%)                       

  ART use at the time of diagnosis   83 (87%)         193 (84%)      279 (84%)      555 (81%)      5 (71%)         112 (87%)      117 (82%)      672 (85%)       0.856^d^      0.599^d^

  CD4+ (cells/µL)                    632\             557\           630\           613\           378\            580\           577\           609\            0.181^b^      0.155^c^
                                     (489--752)       (420--808)     (476--794)     (456--794)     (180--803)      (445--739)     (439--741)     (453--784)                    

  CD4+/CD8+ ratio                    0.59\            0.57\          0.59\          0.58\          0.44\           0.56\          0.56\          0.58\           0.235^b^      0.405^c^
                                     (0.42--0.78)     (0.37--0.79)   (0.43--0.81)   (0.41--0.80)   (0.15--0.60)    (0.40--0.80)   (0.40--0.79)   (0.41--0.80)                  

  HIV-RNA \<50 copies/mL             65 (67%)         156 (66%)      262 (75%)      483 (70%)      5 (83%)         93 (69%)       98 (69%)       581 (70%)       0.155^d^      0.919^d^

  Treatment response                 90 (93%)         219 (92%)      304 (87%)      613 (89%)      5 (83%)         114 (84%)      119 (83%)      732 (88%)       0.045^d^      0.045^d^
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results are described by median (Q1--Q3) or frequency (%), as appropriate.

Abbreviations: Q1, quartile 1; Q3, quartile 3; RPR, rapid plasma regain; TPHA, *Treponema pallidum* hemagglutination assay; BPG, benzathine penicillin G; ART, antiretroviral therap.

^a^overall p-values refer to the simultaneous comparison of primary vs. secondary vs. early latent vs. tertiary vs. late latent syphilis.

^b^by Kruskal-Wallis test.

^c^by Mann-Whitney test.

^d^by chi-square or Fisher's exact test.
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Two hundred thirty-seven (29%) episodes of syphilis were first infections, 592 (71%) were re-infections, and 507 (61%) episodes had an RPR titer ≤1:32 at diagnosis.

BPG was used for the treatment of 738 (89%) cases, and doxycycline was administered in 73 (9%) episodes. For early syphilis, a 1-dose BPG regimen was administered in 175 (26%) cases, a 3-dose BPG regimen was administered in 435 (63%) cases, and doxycycline was administered in 55 (8%) cases. Use of the 1-dose BPG regimen for the treatment of early syphilis increased over time; the 1-dose BPG regimen was used in 22% of diagnoses that were recorded before 2010, in 24% during the 2010--2012 period, and in 41% after 2012 (*P* \< .0001 by the Cochran-Mantel-Haenszel test). During the 2015--2016 period, the 1-dose BPG regimen was used for treatment in 61% of early syphilis episodes.

After treatment, a serological response was observed in 732 (88%) syphilis episodes. The overall incidence rate of treatment response was 110.8 (102.7--118.8) per 1000 PMFU, with a significant increase in the more recent years (before 2010: 80.9 \[70.5--91.2\]/1000 PMFU; 2010--2012: 126.3 \[110.9--141.7\]/1000 PMFU; after 2012: 142.6 \[124.6--160.6\]/1000 PMFU; *P* \< .0001).

The proportions of treatment response were significantly different between early and late syphilis (89% vs 83%, respectively; *P* = .045). With regards to the comparison of early syphilis that was treated with 1 vs 3 doses of BPG, no differences were observed in the frequency of treatment response for any type of syphilis. In primary syphilis, treatment response was observed in 23/25 (95%) episodes that were treated with 1 dose vs 50/54 (93%) episodes that were treated with a 3-dose BPG regimen (*P* = .997); in secondary syphilis, a treatment response was observed in 46/48 (97%) episodes that were treated with 1 dose, compared with 151/165 (91%) episodes that were treated with the 3-dose BPG regimen (*P* = .471); in early latent syphilis: treatment response in 90/102 (88%) episodes that were treated with 1 dose, vs 193/216 (89%) episodes that were treated with a 3-dose BPG regimen (*P* = .841); in all early syphilis episodes: 159/175 (91%) episodes that were treated with 1 dose, vs 394/435 (91%) that were treated with a 3-dose BPG regimen (*P* = .999).

The crude incidence rate of treatment response in early syphilis episodes was 120.8 (111.3--130.4) per 1000 PMFU as compared with 77.4 (63.5--91.3)/1000 PMFU among late syphilis episodes (*P* \< .0001). A significant increase in the crude incidence rate of treatment response was found, over time, for early syphilis episodes (before 2010: 88.5 \[75.7--101.3\]/1000 PMFU; 2010--2012: 135.8 \[117.6--153.9\]/1000 PMFU; after 2012: 151.3 \[131.1--171.5\]/1000 PMFU; *P* \< .0001), whereas a marginally significant increase was observed for late syphilis (before 2010: 61.1 \[44.0--78.2\]/1000 PMFU; 2010--2012: 94.2 \[66.4--122.0\]/1000 PMFU; after 2012: 96.9 \[59.6--134.1\]/1000 PMFU; *P* = .056).

Subjects' characteristics at their first syphilis episode during the study period are detailed in [Table 2](#T2){ref-type="table"} according to syphilis stage.

###### 

Characteristics at First Syphilis Episode During the Study Period (January 1, 2004--June 30, 2016) of the 564 People Living With HIV who Were Included in the Study; HIV Clinic of San Luigi Center, San Raffaele Hospital, Milan, Italy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics             All Syphilis\   Early Syphilis                                                Late Syphilis                                 Overall^a^\   Early vs Late\
                              (n = 564)                                                                                                                   *P* Value     *P* Value
  --------------------------- --------------- ---------------- -------------- -------------- -------------- --------------- -------------- -------------- ------------- ----------------
  Age, y                      41.6\           42.7\            40.1\          41.6\          41.3\          42.9\           43.4\          43.4\          .028^b^       .008^c^
                              (36.2--47.6)    (37.2--49.2)     (34.9--47.2)   (35.7--47.0)   (35.5--47.3)   (39.6--46.5)    (38.3--49.7)   (38.4--49.6)                 

  Ethnicity                                                                                                                                               .391^d^       .397^d^

  White                       497 (88)        61 (85)          153 (87)       188 (91)       402 (89)       3 (100)         92 (85)        95 (86)                      

  Other                       67 (12)         11 (15)          22 (13)        18 (9)         41 (9)         0               16 (15)        16 (14)                      

  Male gender                 562 (99.6)      72 (100)         173 (99)       206 (100)      451 (99.5)     3 (100)         108 (100)      108 (100)      .347^d^       .999^d^

  HIV risk factor                                                                                                                                         .064^d^       .109^d^

  MSM                         499 (88)        64 (89)          150 (86)       193 (94)       407 (90)       2 (67)          90 (82)        92 (83)                      

  PWID                        7 (1)           0                4 (2)          1 (1)          5 (1)          0               2 (2)          2 (2)                        

  Heterosexual                26 (5)          2 (3)            8 (5)          7 (3)          17 (4)         1 (33)          8 (7)          9 (8)                        

  Other/unknown               32 (6)          6 (8)            13 (7)         5 (2)          24 (5)         0               8 (9)          8 (7)                        

  Years since HIV diagnosis   7.6\            8.5\             6.7\           6.7\           6.8\           4.1\            10.9\          10.4\          .012^b^       .001^c^
                              (3.4--13.1)     (3.2--14.3)      (3.0--12.4)    (2.8--12.1)    (3.0--12.4)    (0.4--23.0)     (5.7--14.5)    (5.6--14.5)                  

  Years of ART                4.9\            5.3\             3.8\           4.2\           4.0\           4.0\            7.1\           7.0\           .097^b^       .011^c^
                              (1.0--10.6)     (0.8--12.0)      (0.9--9.7)     (0.7--10.2)    (0.8--10.2)    (0--17.6)       (2.9--11.4)    (2.8--11.4)                  

  Naïve                       104 (19)        12 (17)          34 (19)        41 (20)        87 (19)        1 (33)          16 (15)        17 (15)        .746^d^       .413^d^

  Nadir CD4+, cells/µL        310\            330\             319\           307\           315\           31\             299\           294\           .023^b^       .012^c^
                              (202--411)      (225--407)       (198--425)     (204--433)     (207--425)     (19--164)       (193--356)     (189--356)                   

  Previous AIDS diagnosis     62 (11)         5 (7)            18 (10)        23 (11)        46 (10)        1 (33)          15 (14)        16 (14)        .440^d^       .235^d^

  HCV antibodies                                                                                                                                          .056^d^       .243^d^

  Negative                    492 (87)        63 (87)          158 (90)       175 (85)       396 (87)       2 (67)          95 (88)        97 (87)                      

  Positive                    53 (9)          4 (6)            14 (8)         27 (13)        45 (10)        1 (33)          7 (6)          8 (7)                        

  Unknown                     18 (3)          5 (7)            3 (2)          4 (2)          12 (3)         0               6 (6)          6 (5)                        

  HBsAg                                                                                                                                                   .167^d^       .225^d^

  Negative                    404 (72)        51 (71)          139 (80)       140 (68)       330 (73)       3 (100)         72 (67)        75 (68)                      

  Positive                    29 (5)          4 (6)            6 (3)          15 (7)         25 (6)         0               4 (4)          4 (4)                        

  Unknown                     130 (23)        17 (22)          30 (17)        51 (25)        98 (22)        0               32 (29)        32 (29)                      

  CD4+, cells/µL              584\            614\             550\           610\           597\           102\            564\           558\           .112^b^       .254^c^
                              (438--754)      (472--727)       (413--784)     (445--758)     (442--764)     (24--180)       (441--695)     (427--693)                   

  CD4+/CD8+ ratio             0.55\           0.58\            0.55\          0.57\          0.56\          0.11\           0.52\          0.50\          .053          .309^c^
                              (0.38--0.78)    (0.38--0.76)     (0.34--0.77)   (0.42--0.80)   (0.38--0.78)   (0.07--0.15)    (0.39--0.76)   (0.38--0.76)                 

  HIV-RNA \<50 copies/mL      364 (65)        47 (65)          100 (58)       148 (72)       295 (65)       1 (33)          69 (65)        70 (63)        .067^d^       .999^d^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results are described by median (Q1--Q3) or frequency (%), as appropriate.

Abbreviations: ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; MSM, men who have sex with men; PWID, people who inject drugs.

^a^Overall *P* values refer to the simultaneous comparison of primary vs secondary vs early latent vs tertiary vs late latent syphilis.

^b^By Kruskal-Wallis test.

^c^By Mann-Whitney test.

^d^By chi-square or Fisher exact test.

The median age of the 564 subjects included in the study was 41.6 (36.2--47.6) years, 561 (99.6%) were males, 499 (88%) were MSM, they were HIV-infected for 7.6 (3.4--13.1) years, 82 (14%) were hepatitis C virus-- or hepatitis B virus--coinfected, 104 (19%) were antiretroviral therapy (ART)--naïve, and 364 (65%) had HIV-RNA \<50 copies/mL, a CD4+ level of 584 (438--754) cells/mm^3^, and a nadir CD4+ of 310 (202--411) cells/mm^3^.

The CD4+ cell count at syphilis diagnosis increased over time: a median of 551 (411--749) cells/mm^3^ for syphilis episodes that were diagnosed before 2008, 568 (415--766) cells/mm^3^ for episodes that were diagnosed between 2008 and 2011, and 644 (506--823) cells/mm^3^ for syphilis episodes that were diagnosed after 2011 (*P* = .001 by Kruskal-Wallis test).

Three hundred seventy-four (66%) subjects had a single episode of syphilis diagnosis during their follow-up, 132 (23%) had 2 episodes, 43 (8%) had 3, 13 (2%) had 4, and 2 patients had 5 syphilis diagnoses during their follow-up.

Results of multivariate analyses on factors that were associated with treatment response for early and late syphilis are detailed in [Table 3](#T3){ref-type="table"}. For episodes of early syphilis, a response to treatment was independently associated with a higher nadir CD4+ cell count (adjusted hazard ratio \[AHR\], 1.06; 95% CI = 1.01--1.12; *P* = .029), an RPR titer \>1:32 (AHR, 1.26; 95% CI, 1.06--1.51; *P* = .009), and a diagnosis that had been made in more recent calendar years (AHR, 1.36; 95% CI, 1.17--1.59; *P* \< .001). Additionally, subjects with early latent syphilis had a similar risk of treatment response compared with those with primary syphilis but a lower risk when compared with those with secondary syphilis (AHR, 0.78; 95% CI, 0.64--0.93; *P* = .008).

###### 

Multivariate Cox Proportion Hazards Models for Recurrent Events: Factors Associated With Treatment Response

  Characteristic                                      Overall                       Early Syphilis                Late Syphilis       
  --------------------------------------------------- ------------------- --------- ------------------- --------- ------------------- ------
  Age, per 5 y longer                                 0.97 (0.92--1.03)   .331      0.97 (0.91--1.03)   .325      1.00 (0.88--1.13)   .945
  Years of antiretroviral treatment, per 5 y longer   0.98 (0.90--1.05)   .539      1.00 (0.92--1.09)   .950      0.81 (0.64--1.02)   .071
  Nadir CD4+, per 100 cells/µL higher                 1.04 (1.0--1.09)    .078      1.06 (1.01--1.12)   .029      1.04 (0.91--1.19)   .611
  Type of syphilis                                                                                                                    
  Early vs late                                       1.25 (0.98--1.58)   .070                                    Not included        \-
  Primary vs early latent                             Not included        \-        1.23 (0.93--1.64)   .152      Not included        \-
  Secondary vs early latent                           Not included        \-        1.29 (1.07--1.56)   .008      Not included        \-
  Primary vs secondary                                Not included        \-        0.95 (0.71--1.28)   .749      Not included        \-
  Calendar year of diagnosis, per 1 y longer          1.41 (1.22--1.62)   \<.0001   1.36 (1.17--1.59)   \<.0001   1.62 (1.14--2.31)   .007
  First infection, yes vs no                          1.28 (1.04--1.57)   .021      1.15 (0.92--1.45)   .224      1.80 (1.07--3.03)   .027
  RPR titer at diagnosis, \>1:32 vs ≤1:32             1.41 (1.19--1.64)   \<.0001   1.27 (1.06--1.52)   .009      2.04 (1.30--3.23)   .002
  CD4+/CD8+ ratio, per 20% higher                     1.02 (0.97--1.06)   .456      1.01 (0.96--1.07)   .687      1.01 (0.91--1.13)   .833
  HIV-RNA, per log~10~ copies/mL higher               1.00 (0.92--1.09)   .944      1.03 (0.94--1.12)   .547      0.80 (0.63--1.01)   .061
  Treatment regimens                                                                                                                  
  Doxycycline vs BPG                                  1.15 (0.80--1.66)   .445      Not included                  Not included        \-
  1-dose BPG vs 3-dose BPG                            Not included                  0.97 (0.73--1.60)   .811      Not included        \-
  Doxycycline vs 3-dose BPG                           Not included                  1.08 (0.89--1.77)   .719      1.48 (0.80--2.73)   .216
  Doxycycline vs 1-dose BPG                           Not included        \-        1.11 (0.72--1.69)   .648      Not included        \-

Abbreviations: AHR, adjusted hazard ratio; BPG, benzathine penicillin G; CI, confidence interval; RPR, rapid plasma reagin.

Treatment response for late syphilis was higher in first infections (AHR, 1.80; 95% CI, 1.07--3.03; *P* = .027) and in more recent calendar years (AHR, 1.62; 95% CI, 1.14--2.31; *P* = .007). Additionally, treatment response for late syphilis was associated with a higher RPR titer at diagnosis (AHR, 2.04; 95% CI, 1.29--3.23; *P* = .002). Interestingly, the risk of treatment response was not found to be associated with any of the treatment regimens in all the estimated models (overall, early, and late syphilis diagnoses).

Finally, serofast status was diagnosed in 82/335 (25%) of the patients with a single diagnosis of syphilis during the study period (early syphilis, 73/277 \[26%\]; late syphilis, 9/58 \[16%\]; *P* = .094). Predictors of serofast status are reported in [Table 4](#T4){ref-type="table"}.

###### 

Multivariate Cox Proportion Hazards Models: Factors Associated With Serofast Response

  Characteristic                                      Overall                       Early Syphilis      
  --------------------------------------------------- ------------------- --------- ------------------- ---------
  Age, per 5 y longer                                 0.98 (0.81--1.19)   .849      0.93 (0.75--1.17)   .537
  Years of antiretroviral treatment, per 5 y longer   1.38 (1.06--1.79)   .020      1.30 (0.95--1.77)   .098
  Nadir CD4+, per 100 cells/µL higher                 0.80 (0.66--0.98)   .019      0.75 (0.59--0.96)   .020
  Type of syphilis                                                                                      
  Early vs late                                       3.55 (1.50--8.40)   .040                          
  Primary vs early latent                             Not included        \-        1.91 (0.96--3.80)   .066
  Secondary vs early latent                           Not included        \-        0.81 (0.42--1.56)   .532
  Primary vs secondary                                Not included        \-        2.35 (1.04--5.31)   .040
  Calendar year of diagnosis, per 1 y longer          0.67 (0.59--0.76)   \<.0001   0.59 (0.50--0.70)   \<.0001
  First infection, yes vs no                          0.73 (0.42--1.27)   .268      0.71 (0.38--1.32)   .281
  RPR titer at diagnosis, \>1:32 vs ≤1:32             1.01 (0.61- 1.65)   .982      1.35 (0.80--2.28)   .266
  CD4+/CD8+ ratio, per 20% higher                     1.01 (0.87--1.17)   .924      1.15 (0.92--1.43)   .230
  HIV-RNA, per log~10~ copies/mL higher               1.13 (0.89--1.43)   .325      1.10 (0.86--1.42)   .448
  Treatment regimens                                                                                    
  Doxycycline vs BPG                                  1.32 (0.38--4.59)   .664      Not included        
  1-dose BPG vs 3-dose BPG                            Not included        \-        2.40 (1.25--4.62)   .009
  Doxycycline vs 3-dose BPG                           Not included        \-        1.59 (0.48--5.22)   .446
  Doxycycline vs 1-dose BPG                           Not included        \-        0.66 (0.20--2.25)   .510

The multivariate model on factors associated with serofast response among subjects with late syphilis was not calculated because of the low sample size (9 serofast responses among 58 late syphilis patients).

Abbreviations: AHR, adjusted hazard ratio; BPG, benzathine penicillin G; CI, confidence interval; RPR, rapid plasma reagin.

DISCUSSION {#s4}
==========

In our cohort of PLWH, 863 episodes of syphilis in 584 subjects were observed between January 2004 and June 2016. More recent years of the study reported a higher incidence of syphilis, similar to other studies \[[@CIT0008], [@CIT0020]\].

Almost all of the subjects were males, and approximately 90% were MSM. The high prevalence of syphilis in MSM living with HIV has been described \[[@CIT0021]\] and is associated with a reduction in the awareness of sexually transmitted infections and high-risk sexual behaviors in this population \[[@CIT0022]\]. With regards to these issues, in this study, 71% of the infections occurred in individuals with a history of syphilis (re-infections) and 34% of the subjects had more than 1 syphilis diagnosis during the follow-up period, indicating the recurrence of high-risk sexual behaviors in our patients.

Overall, subjects included in our study showed good immune-virological status. At the time of diagnosis of syphilis, the median CD4+ cell count was approximately 600 cells/mm^3^, 81% had received some form of antiretroviral treatment, and 80% of treated subjects had a viremia of \<50 copies/mL.

Despite the fact that the 3-dose BPG regimen remains the more frequently prescribed treatment, including among early syphilis diagnoses (63% of the total episodes), the 1-dose BPG treatment has recently become the preferred regimen for treatment of early syphilis, in accordance with guidelines and recommendations \[[@CIT0012], [@CIT0013]\].

Treatment failure was observed in 12% of episodes that were included in the study, which is a proportion that is similar to what has been observed in other studies regarding uninfected individuals \[[@CIT0011]\] and PLWH in the post-ART era \[[@CIT0009], [@CIT0010]\].

Additionally, differences were observed in the proportions of subjects who responded to treatment when diagnosed with early and late syphilis. This finding is similar to what has been reported by other studies \[[@CIT0007], [@CIT0023]\] and confirms that subjects with late syphilis diagnoses are at a higher risk for serologically defined treatment failure, although, in our study, different time points were used to evaluate for a response in early and late syphilis, as suggested by the Centers for Disease Control and Prevention \[[@CIT0012]\]. These time points, although established, are arbitrary. Therefore, it is possible that if the period of testing for treatment response was extended, the proportion of responders would increase.

According to the different clinical characteristics and criteria for serological response, we decided to separately analyze early and late syphilis to evaluate predictors of treatment response.

Treatment response in episodes of early syphilis was independently associated with a higher nadir CD4+ cell count, an RPR titer \>1:32, and a diagnosis made in more recent calendar years. Additionally, episodes of early latent syphilis had a lower risk of treatment response when compared with episodes of secondary syphilis.

Immunosuppression has been associated with treatment failure in syphilis, as reported in previous studies on PLWH \[[@CIT0010], [@CIT0022]\] and subjects with an impaired immune system have been reported to respond more slowly to syphilis treatment, compared with those with a good immunological status \[[@CIT0010], [@CIT0024]\]. In this study, higher RPR titers were associated with treatment response both in early and late syphilis. This finding has been described in HIV-negative and HIV-infected individuals \[[@CIT0011]\]. Higher RPR titers may reflect a more potent immunological response, which is associated with a more efficacious clearance of *Treponema pallidum* \[[@CIT0025]\]. Additionally, subjects with lower RPR titers may have a longer duration of infection, with lower metabolic activity of the microorganism and a delayed response to treatment \[[@CIT0026]\]. Finally, a 4-fold decline in the RPR titer (the definition of treatment response) is more easily obtained in patients with higher titers at the time of diagnosis of syphilis \[[@CIT0010]\].

The calendar year of syphilis diagnosis was another predictor of treatment response both in early and late syphilis. Episodes that were diagnosed in less recent years had a lower risk of response, compared with the more recent diagnoses. This finding is probably related to the lower CD4+ cell count observed in subjects with a diagnosis in less recent years, and the possible consequent delay in treatment response.

In late syphilis, re-infections were associated with a higher risk of treatment failure than in patients at their first infection. This result is similar to that described in PLWH by Jinno et al. \[[@CIT0010]\], although it is unclear why this association was not observed for early syphilis cases in this study.

The risk of treatment response was not found to be associated with the treatment regimens in early and late syphilis. In other studies \[[@CIT0009], [@CIT0010], [@CIT0014]\], which are in agreement with these results, a 1-dose BPG regimen for PLWH showed an efficacy that was similar to that of the 3-dose BPG regimen; it should be considered the firstline regimen in treatment of episodes of early syphilis among PLWH, in accordance with current international guidelines.

In our study, doxycycline demonstrated a similar efficacy as BPG, also in patients with late latent syphilis, although this result should be interpreted with caution because of the small number of patients that were treated with doxycycline at this disease stage.

The optimal management of patients who failed to demonstrate a treatment response is unclear. Because treatment failure might be the result of central nervous system involvement, cerebrospinal fluid (CSF) examination can be considered \[[@CIT0012]\]. If the CSF examination is negative, retreatment should be administered, although serologic titers might not decline despite repeated courses of therapy \[[@CIT0027]\].

Of interest is the finding that 25% of the patients did not serovert their nontreponemal test titers during the follow-up period (serofast status), despite an appropriate decline of their RPR titers. These subjects had a serologically defined cure, although the persistence of a positive RPR titer may represent a concern for the clinician because of the paucity of data regarding the long-term management and outcomes of these patients.

Data regarding serofast status, especially among PLWH, are lacking. In this study, a lower nadir CD4+, a longer duration of antiretroviral treatment, a diagnosis of early syphilis as compared with late syphilis, and a less recent calendar year of syphilis infection were associated with serofast status. Interestingly, the restricted analysis on early syphilis episodes showed that a serofast status was related to a diagnosis of primary syphilis, as compared with a secondary syphilis diagnosis; it was also related to the use of a 1-dose BPG treatment, as compared with a 3-dose BPG schedule.

Our study has several limitations. First, we cannot exclude the possibility of selection bias, as 4% of the total syphilis episodes were excluded because of incomplete information or loss to follow-up. Second, given the retrospective nature of the study, the included subjects had different follow-up durations and were differently distributed over time. Third, in our definition of re-infection, syphilis episodes that occurred in PLWH who seroconverted their RPR titers (if previously negative) were included. However, HIV infection has been associated with false-positive, low RPR titers \[[@CIT0028]\], and thus syphilis re-infections may have been overdiagnosed, especially among those who seroconverted with a low RPR titer (≤1:2) and were diagnosed with latent syphilis (early and late). Therefore, we performed additional sensitivity analyses after the exclusion of these episodes (n = 30) by recalculating the multivariable analyses of [Table 3](#T3){ref-type="table"} after excluding these 30 cases. The results (Supplementary Table 1) were similar to those already reported herein. Finally, it was not ensured that the subjects did not utilize other antibiotics that were active against *Treponema pallidum* in between their follow-up visits. Nonetheless, this is one of the largest studies that has investigated predictors of treatment response in PLWH diagnosed with syphilis, and it had a long follow-up period.

In conclusion, a higher incidence of syphilis was observed in the more recent years of this study, with an overall serological response of 88%. For episodes of early syphilis, factors that were associated with the serological treatment response were a higher nadir CD4+ cell count, an RPR titer \>1:32, a diagnosis that was recorded in more recent years, and a secondary syphilis diagnosis (when compared with early latent syphilis). In subjects that were diagnosed with late syphilis, a serological treatment response was associated with first infection, a diagnosis in more recent years, and higher RPR titers.
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